enGene Therapeutics (ENGN) Preferred Stock Liabilities (2022 - 2023)
enGene Therapeutics (ENGN) posted Preferred Stock Liabilities of $53.12 million for fiscal Q2 2023 (quarter ended Apr 30, 2023), unchanged from the prior quarter.
Analysis
enGene Therapeutics (ENGN) Preferred Stock Liabilities (2022 - 2023) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | - |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | - |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | - |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | - |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | - |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | - |
| 10 | enGene Therapeutics | 134.03 Mn | 134.03 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2023 | 53.12 Mn |
| Jan 31, 2023 | 53.12 Mn |
| Oct 31, 2022 | 53.12 Mn |
API Access
enGene Therapeutics Preferred Stock Liabilities API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=ENGN&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "preferred-stock-liabilities", "ticker": "ENGN", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=ENGN&period=max&api_key=YOUR_API_KEY");
const data = await res.json();